SEPTERNA INC (SEPN) — insider trading
Health Care · NASDAQ
SEPTERNA INC (SEPN) has 67 reported SEC Form 4 insider transactions in our data, including 24 open-market sales among the most recent 67 (latest 2026-10-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion (derivative) | 4,000 | — | $0 | Form 4 |
| 2026-10-15 | Bhatt Elizabeth | Officer (President and COO) | Open-market sale | 2,906 | $37.61 | $109.3K | Form 4 |
| 2026-10-15 | Bhatt Elizabeth | Officer (President and COO) | Open-market sale | 1,094 | $36.87 | $40.3K | Form 4 |
| 2026-10-15 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion | 4,000 | $6.81 | $27.2K | Form 4 |
| 2026-09-08 | Patni Rajiv | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 275,000 | — | $0 | Form 4 |
| 2026-09-01 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion (derivative) | 3,333 | — | $0 | Form 4 |
| 2026-09-01 | Long Daniel D. | Officer (SVP, Drug Discovery) | Open-market sale | 3,333 | $37.83 | $126.1K | Form 4 |
| 2026-09-01 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion | 3,333 | $2.76 | $9.2K | Form 4 |
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market sale | 746,500 | $42.50 | $31.73M | Form 4 |
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market sale | 746,500 | $42.50 | $31.73M | Form 4 |
| 2026-08-12 | Third Rock Ventures V, L.P.; Third Rock Ventures GP V, LP; TRV GP V, LLC; Third Rock Ventures VI, L.P.; Third Rock Ventures GP VI, L.P.; TRV GP VI, LLC | 10% owner | Open-market sale | 141 | $51.08 | $7.2K | Form 4 |
| 2026-08-12 | Third Rock Ventures V, L.P.; Third Rock Ventures GP V, LP; TRV GP V, LLC; Third Rock Ventures VI, L.P.; Third Rock Ventures GP VI, L.P.; TRV GP VI, LLC | 10% owner | Open-market sale | 147,059 | $50.27 | $7.39M | Form 4 |
| 2026-08-11 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion (derivative) | 6,319 | — | $0 | Form 4 |
| 2026-08-11 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion (derivative) | 18,681 | — | $0 | Form 4 |
| 2026-08-11 | Bhatt Elizabeth | Officer (President and COO) | Open-market sale | 25,000 | $44.00 | $1.10M | Form 4 |
| 2026-08-11 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion | 6,319 | $2.76 | $17.4K | Form 4 |
| 2026-08-11 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion | 18,681 | $6.81 | $127.2K | Form 4 |
| 2026-08-03 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion (derivative) | 1,518 | — | $0 | Form 4 |
| 2026-08-03 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion (derivative) | 1,816 | — | $0 | Form 4 |
| 2026-08-03 | Long Daniel D. | Officer (SVP, Drug Discovery) | Open-market sale | 2,334 | $34.68 | $80.9K | Form 4 |
| 2026-08-03 | Long Daniel D. | Officer (SVP, Drug Discovery) | Open-market sale | 1,000 | $33.98 | $34.0K | Form 4 |
| 2026-08-03 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion | 1,518 | $2.76 | $4.2K | Form 4 |
| 2026-08-03 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion | 1,816 | $2.76 | $5.0K | Form 4 |
| 2026-07-15 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion (derivative) | 4,000 | — | $0 | Form 4 |
| 2026-07-15 | Bhatt Elizabeth | Officer (President and COO) | Open-market sale | 4,000 | $33.99 | $136.0K | Form 4 |
| 2026-07-15 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion | 4,000 | $6.81 | $27.2K | Form 4 |
| 2026-07-01 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion (derivative) | 3,333 | — | $0 | Form 4 |
| 2026-07-01 | Long Daniel D. | Officer (SVP, Drug Discovery) | Open-market sale | 1,233 | $34.81 | $42.9K | Form 4 |
| 2026-07-01 | Long Daniel D. | Officer (SVP, Drug Discovery) | Open-market sale | 2,100 | $34.10 | $71.6K | Form 4 |
| 2026-07-01 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion | 3,333 | $2.76 | $9.2K | Form 4 |
| 2026-06-29 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 2,178 | — | $0 | Form 4 |
| 2026-06-29 | Shaikhly Samira | Officer (Chief People Officer) | Open-market sale | 2,178 | $35.18 | $76.6K | Form 4 |
| 2026-06-29 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion | 2,178 | $6.81 | $14.8K | Form 4 |
| 2026-06-26 | Simson Jake | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-06-26 | Ezekowitz Alan | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-06-26 | Gottesdiener Keith Michael | Director | Grant / award / vesting (derivative) | 11,260 | — | $0 | Form 4 |
| 2026-06-26 | Tong Jeffrey K | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-06-26 | Coulie Bernard | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-06-26 | Sharp Shalini | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-06-26 | Bassan Abraham | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-06-26 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-06-22 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion (derivative) | 4,471 | — | $0 | Form 4 |
| 2026-06-22 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion (derivative) | 10,529 | — | $0 | Form 4 |
| 2026-06-22 | Long Daniel D. | Officer (SVP, Drug Discovery) | Open-market sale | 7,000 | $35.97 | $251.8K | Form 4 |
| 2026-06-22 | Long Daniel D. | Officer (SVP, Drug Discovery) | Open-market sale | 8,000 | $35.10 | $280.8K | Form 4 |
| 2026-06-22 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion | 4,471 | $11.70 | $52.3K | Form 4 |
| 2026-06-22 | Long Daniel D. | Officer (SVP, Drug Discovery) | Option exercise / conversion | 10,529 | $2.76 | $29.1K | Form 4 |
| 2026-06-12 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 6,250 | — | $0 | Form 4 |
| 2026-06-12 | Shaikhly Samira | Officer (Chief People Officer) | Open-market sale | 6,250 | $35.08 | $219.2K | Form 4 |
| 2026-06-12 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion | 6,250 | $11.70 | $73.1K | Form 4 |
| 2026-06-01 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 637 | — | $0 | Form 4 |
| 2026-06-01 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 943 | — | $0 | Form 4 |
| 2026-06-01 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 4,355 | — | $0 | Form 4 |
| 2026-06-01 | Shaikhly Samira | Officer (Chief People Officer) | Open-market sale | 2,889 | $29.66 | $85.7K | Form 4 |
| 2026-06-01 | Shaikhly Samira | Officer (Chief People Officer) | Open-market sale | 1,346 | $28.79 | $38.8K | Form 4 |
| 2026-06-01 | Shaikhly Samira | Officer (Chief People Officer) | Open-market sale | 1,700 | $27.78 | $47.2K | Form 4 |
| 2026-06-01 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion | 637 | $2.76 | $1.8K | Form 4 |
| 2026-06-01 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion | 943 | $2.76 | $2.6K | Form 4 |
| 2026-06-01 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion | 4,355 | $1.55 | $6.8K | Form 4 |
| 2026-05-26 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 11,798 | — | $0 | Form 4 |
| 2026-05-26 | Shaikhly Samira | Officer (Chief People Officer) | Open-market sale | 11,798 | $30.06 | $354.7K | Form 4 |
| 2026-05-26 | Shaikhly Samira | Officer (Chief People Officer) | Option exercise / conversion | 11,798 | $6.81 | $80.3K | Form 4 |
| 2026-04-15 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion (derivative) | 4,000 | — | $0 | Form 4 |
| 2026-04-15 | Bhatt Elizabeth | Officer (President and COO) | Open-market sale | 326 | $25.86 | $8.4K | Form 4 |
| 2026-04-15 | Bhatt Elizabeth | Officer (President and COO) | Open-market sale | 1,101 | $25.24 | $27.8K | Form 4 |
| 2026-04-15 | Bhatt Elizabeth | Officer (President and COO) | Open-market sale | 2,573 | $23.76 | $61.1K | Form 4 |
| 2026-04-15 | Bhatt Elizabeth | Officer (President and COO) | Option exercise / conversion | 4,000 | $6.81 | $27.2K | Form 4 |
Ask the chat about SEPN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: SEPTERNA INC (SEPN).
Last updated 2026-10-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.